The Coalition for Epidemic Preparedness Innovations (CEPI) has pledged $60 million to accelerate Ebola vaccine development. Photo: Medical Report.
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced a $60 million funding initiative to fast-track the development of an Ebola vaccine, according to Reuters. This investment aims to leverage advancements in biotechnology and global health partnerships to combat the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC).
A significant portion of the funding will be allocated to Moderna, a biotechnology company that gained global recognition during the COVID-19 pandemic for its mRNA vaccine platform. A collaboration between the University of Oxford and the Serum Institute of India will receive support for a vaccine candidate utilizing similar mRNA technology to that used in COVID-19 vaccines. This project is expected to enter clinical trials within six weeks.
The funding also supports the International AIDS Vaccine Initiative’s (IAVI) efforts to develop treatment options for Ebola. This initiative builds on prior research into other Ebola strains, utilizing existing data to shorten the development timeline.
Richard Hatchett, CEO of CEPI, emphasized that lessons learned during the COVID-19 pandemic have significantly accelerated vaccine development. “Current technology platforms have demonstrated the ability to transition a vaccine candidate from research to clinical trials in as little as two months,” Hatchett stated. However, he acknowledged the inherent risks and uncertainties in vaccine development, which remain complex and unpredictable.
The current Ebola outbreak is the third-largest since the disease’s first appearance in the DRC in 1976. Photo: Xinhua.
As of the latest reports from the Africa Centres for Disease Control and Prevention (Africa CDC) and the World Health Organization (WHO), the DRC has recorded 906 suspected Ebola cases, including 223 deaths potentially linked to the virus. However, the government has confirmed 282 cases and 42 deaths. This outbreak is the third-largest in the DRC since the virus was first identified in 1976, highlighting the urgent need for effective prevention and treatment strategies.
Ngoc Lien